ijms-logo

Journal Browser

Journal Browser

Molecular Mechanisms and Immunotherapy of Soft Tissue and Bone Sarcomas

A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".

Deadline for manuscript submissions: 20 February 2025 | Viewed by 4346

Special Issue Editors


E-Mail Website
Guest Editor
Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA 94305, USA
Interests: immunotherapy of sarcomas

E-Mail Website
Guest Editor
Stanford Cancer Institute, Stanford University Medical Center, Stanford, CA 94305, USA
Interests: bioinformatics; genomic profiling of sarcoma; sarcoma immunotherapy

Special Issue Information

Dear Colleagues,

We would like to call for your attention of this Special Issue of International Journal of Molecular Sciences (IJMS). In this Special Issue, we plan to publish a collection of articles focusing on elucidating the molecular mechanisms of immunotherapy for soft tissue and bone sarcoma, including immune checkpoint inhibitors, adoptive cell therapy, chimeric antigen T-cell receptor (CAR-T), cancer vaccines, and others. Unlike the substantial advances made on the immunotherapy of many common malignancies such as lung cancer, melanoma, renal cell carcinoma over the past decade, sarcoma has seen only limited progress. What are the molecular mechanisms of resistance to immunotherapy? What major issues that remain to be understood for moving the field forward? What are the promising leads in the research pipeline that are likely to bring substantial advances? What are some of the future directions for tackling sarcoma? We very much appreciate your contribution to this field of sarcoma research by contributing your articles to this Special Issue.

Dr. Minggui Pan
Dr. Nam Quoc Bui
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue polices can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

16 pages, 1179 KiB  
Review
Treatment of De-Differentiated Liposarcoma in the Era of Immunotherapy
by Maggie Y. Zhou, Nam Q. Bui, Gregory W. Charville, Kristen N. Ganjoo and Minggui Pan
Int. J. Mol. Sci. 2023, 24(11), 9571; https://doi.org/10.3390/ijms24119571 - 31 May 2023
Cited by 6 | Viewed by 3871
Abstract
Well-differentiated/de-differentiated liposarcoma (WDLPS/DDLPS) is one of the most common histologic subtypes of soft tissue sarcoma (STS); however, treatment options remain limited. WDLPS and DDLPS both exhibit the characteristic amplification of chromosome region 12q13-15, which contains the genes CDK4 and MDM2. DDLPS exhibits [...] Read more.
Well-differentiated/de-differentiated liposarcoma (WDLPS/DDLPS) is one of the most common histologic subtypes of soft tissue sarcoma (STS); however, treatment options remain limited. WDLPS and DDLPS both exhibit the characteristic amplification of chromosome region 12q13-15, which contains the genes CDK4 and MDM2. DDLPS exhibits higher amplification ratios of these two and carries additional genomic lesions, including the amplification of chromosome region 1p32 and chromosome region 6q23, which may explain the more aggressive biology of DDLPS. WDLPS does not respond to systemic chemotherapy and is primarily managed with local therapy, including multiple resections and debulking procedures whenever clinically feasible. In contrast, DDLPS can respond to chemotherapy drugs and drug combinations, including doxorubicin (or doxorubicin in combination with ifosfamide), gemcitabine (or gemcitabine in combination with docetaxel), trabectedin, eribulin, and pazopanib. However, the response rate is generally low, and the response duration is usually short. This review highlights the clinical trials with developmental therapeutics that have been completed or are ongoing, including CDK4/6 inhibitors, MDM2 inhibitors, and immune checkpoint inhibitors. This review will also discuss the current landscape in assessing biomarkers for identifying tumors sensitive to immune checkpoint inhibitors. Full article
Show Figures

Figure 1

Back to TopTop